Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987551 | 0.90 | CYP1A2 (0.45) | CYP1A2HRH3CYP2C19SMN1; SMN2SLC6A1 | |
| SCHEMBL2982368 | 0.84 | HRH3 (0.64) | CYP1A2HRH3CYP2C19SMN1; SMN2SLC6A9 | |
| SCHEMBL2982530 | 0.79 | EGFR (0.41) | CYP1A2HRH3CYP2C19EGFRLCK | |
| SCHEMBL2987386 | 0.78 | SPHK2 (0.49) | HRH3 | |
| SCHEMBL2982535 | 0.78 | EGFR (0.40) | CYP1A2CYP2C19EGFRLCKCD274 | |
| SCHEMBL2988327 | 0.77 | CYP2C19 (0.47) | CYP1A2HRH3CYP2C19SMN1; SMN2SLC6A1 | |
| SCHEMBL1116547 | 0.75 | ALDH1A1 (0.56) | CYP1A2HRH3CYP2C19SMN1; SMN2 | |
| SCHEMBL2032734 | 0.75 | ALDH1A1 (0.56) | CYP1A2HRH3CYP2C19SMN1; SMN2 | |
| SCHEMBL6601839 | 0.74 | HRH3 (0.50) | HRH3SMN1; SMN2SLC6A9CD274 | |
| SCHEMBL8122367 | 0.73 | ALDH1A1 (0.40) | CYP1A2HRH3CYP2C19SMN1; SMN2SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | claimed |
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | CYP1A2 277/4885HRH3 2035/4885CYP2C19 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.